These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 36416738)

  • 21. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
    England JT; Gupta V
    Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How I treat myelofibrosis.
    Cervantes F
    Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
    Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
    Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of myelofibrosis: JAK inhibition and beyond.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
    Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
    Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anemia in myelofibrosis: Current and emerging treatment options.
    Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
    Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Not Available].
    Soret J; Kiladjian JJ
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clarifying the use of ruxolitinib in patients with myelofibrosis.
    Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
    Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA; Mesa RA; Hoffman R; Shammo JM
    Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
    Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
    Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
    Stein BL
    Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
    Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
    PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pacritinib: a new agent for the management of myelofibrosis?
    Beauverd Y; McLornan DP; Harrison CN
    Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelofibrosis: an update on current pharmacotherapy and future directions.
    Cervantes F; Martinez-Trillos A
    Expert Opin Pharmacother; 2013 May; 14(7):873-84. PubMed ID: 23514013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
    Deininger M; Radich J; Burn TC; Huber R; Paranagama D; Verstovsek S
    Blood; 2015 Sep; 126(13):1551-4. PubMed ID: 26228487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Clinical Investigations in Myelofibrosis.
    Venugopal S; Mascarenhas J
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):353-373. PubMed ID: 33641874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel therapeutics for myelofibrosis.
    Lee SE
    Blood Res; 2023 Apr; 58(S1):S13-S19. PubMed ID: 36891574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes.
    Rafati M; Brown DW; Zhou W; Jones K; Luo W; St Martin A; Wang Y; He M; Spellman SR; Wang T; Deeg HJ; Gupta V; Lee SJ; Bolon YT; Chanock SJ; Machiela MJ; Saber W; Gadalla SM
    Blood Adv; 2023 Dec; 7(24):7506-7515. PubMed ID: 38011490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
    Tiribelli M; Morelli G; Bonifacio M
    Expert Opin Pharmacother; 2024 Apr; 25(6):743-754. PubMed ID: 38738513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.